The ARO-C3 study is sponsored by Arrowhead Pharmaceuticals, Inc. and is developing ARO-C3 to treat complement-mediated renal diseases (C3G and IgA Nephropathy). ARO-C3 works by blocking production of the complement component 3 (C3) protein in the liver. C3 plays a role in activating the complement cascade in the body's immune system, which can lead to kidney injury from excessive or unsuitable activation of the complement system. ARO-C3 will be administered by subcutaneous injection on Days 1, 29 and 113 of the study.
Clinical Trial
Other
Expenses covered
Participants will receive $250 per study visit as compensation for inconvenience, loss of wages and family care costs while attending study visits. Study participants will also receive reimbursement for travel, parking, meals and other expenses associated with study visits.
Person with early stage kidney disease
Email: [email protected]
Return to research listing page